Adeka (4401) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
23 Oct, 2026Executive summary
Q3 FY2023 net sales JPY 286.4b; operating profit JPY 24.0b; current profit JPY 24.5b; profit attributable to owners of parent JPY 16.4b; EPS JPY 161.
Sales declined, but profit grew; lower sales volume and higher manufacturing and fixed costs were partly offset by net pricing improvements and FX gains.
Financial highlights
Polymer Additives operating profit was reduced by JPY 1.8b from lower volume and JPY 0.4b from fixed costs; positive pricing and FX effects did not offset the declines.
Food products operating profit benefited from JPY 3.7b in net pricing, JPY 0.6b from higher volume and JPY 0.4b from lower manufacturing costs.
Life Science operating profit was pressured by JPY 2.6b from lower volume and JPY 0.6b from higher fixed costs; FX provided a partial offset.
Outlook and guidance
FY2023 forecasts unchanged: sales JPY 410b; operating and current profit JPY 34.5b each; parent-attributable profit JPY 21b; EPS JPY 204.8.
Forecast dividends remain JPY 40 per share at year-end and JPY 80 per share annually.
Segment revisions: lower sales forecasts for Polymer Additives and Electronics & IT Materials; higher food products sales forecast. Electronics & IT Materials operating profit forecast lowered; food products and Other raised.
Original FY2023 ADX 2023 medium-term plan target is expected to be missed; lessons are intended to inform future targets.
Latest events from Adeka
- Q1 earnings fell on volume weakness; FY profit targets stayed intact.document-source184401
Q1 2024 - Record FY2023 profits set the stage for ADX 2026 growth and JPY 75 billion in CapEx.4401
Q4 2024 - Strong sales and profit growth led by chemicals and semiconductors; outlook and dividends raised.4401
Q1 2027 - Record FY2025 results; FY2026 forecasts further growth but exclude Middle East impacts.4401
Q4 2026 - H1 growth lifted FY2024 guidance and dividends, led by Chemicals.4401
Q2 2025 - Nine-month profit rose 25.1%, led by Chemicals, as semiconductor investment advanced.4401
Q3 2025 - Record FY2024 results, with FY2025 growth forecast amid tariff and cost risks.4401
Q4 2025 - Profit and sales rose, led by Life Science, with stable outlook and higher dividend forecast.4401
Q1 2026 - Profit rose on strong Life Science and Environmental Materials, offsetting Chemicals weakness.4401
Q3 2026